Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | SI | P14410 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 7/20 | 0.75 |
| ▸ | MET | P08581 | 1/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | ERN1 | O75460 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 3/20 | 0.67 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Methyldaphnetin SCHEMBL29671915 | 1.00 | MCL1 (1.00) | MCL1GAAKDM4EMGAMALDH1A1 | |
| 4-Methyldaphnetin SCHEMBL1668524 | 0.89 | MCL1 (0.80) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL4187220 | 0.86 | MAOB (1.00) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL5351976 | 0.83 | MET (1.00) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL23143160 | 0.83 | MAOB (0.71) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL8724340 | 0.83 | GAA (1.00) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL10627951 | 0.83 | MAOB (0.71) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL9464086 | 0.83 | MAOB (0.71) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL12858749 | 0.82 | MCL1 (0.69) | MCL1GAAKDM4EMGAMALDH1A1 | |
| SCHEMBL14398970 | 0.81 | ERN1 (1.00) | MCL1GAAKDM4EMGAMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304727-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM GROUP B.V. (NL) | 2025-10-02 | — | — | US | claimed |
| US-12421419-B2 | Preparation method for ultraviolet-responsive coumarin controlled-release and self-repairing anti-fouling paint | Quzhou Research Institute of Zhejiang University (CN) | 2025-09-23 | — | — | US | claimed |
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-03 | — | — | US | claimed |
| EP-4519376-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM Group B.V. (NL) | 2025-03-12 | — | — | EP | claimed |
| CN-118319988-A | A flos Carthami composition effective component extract and its preparation method | 广西壮族自治区花红药业集团股份公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118325263-A | Conductive hydrogel film with glucose response and preparation method and application thereof | 重庆医科大学 | 2024-07-12 | — | — | CN | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| CN-117285823-A | Biological conductive material containing sericin, preparation method and application | 重庆市铜梁区人民医院 | 2023-12-26 | — | — | CN | claimed |
| WO-2023214013-A1 | PHOTOINITIATOR PACKAGE COMPRISING PHOSPHINE OXIDE PHOTOINITIATORS, COUMARIN-BASED SENSITIZERS AND AMINE ADDITIVES | IGM GROUP B. V. (NL) | 2023-11-09 | — | — | WO | claimed |
| CN-115851110-B | Preparation method of light response long-acting super-lubricating anti-fouling paint based on coumarin | 浙江大学 | 2023-08-15 | — | — | CN | claimed |
| US-7838186-B2 | Photoconductors containing charge transport chelating components | XEROX CORPORATION (US) | 2010-11-23 | — | — | US | claimed |
| US-20080286670-A1 | Photoconductors containing charge transport chelating components | XEROX CORPORATION | 2008-11-20 | — | — | US | claimed |
| EP-1282411-A4 | METHOD OF TREATING CANCER | CHARLOTTE MECKLENBURG HOSPITAL (US) | 2008-05-21 | — | — | EP | claimed |
| US-20080009544-A1 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-01-10 | — | — | US | claimed |
| US-20070142462-A1 | Method of Treating Cancer | THE UNIVERSITY OF UTAH | 2007-06-21 | — | — | US | claimed |
| WO-2006024545-A1 | FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2006-03-09 | — | — | WO | claimed |
| US-20040047852-A1 | Method of treating cancer | THE UNIVERSITY OF UTAH | 2004-03-11 | — | — | US | claimed |
| EP-1282411-A1 | METHOD OF TREATING CANCER | Charlotte-Mecklenburg Hospital Authority doing business as Carolinas Medical Center (US) | 2003-02-12 | — | — | EP | claimed |
| WO-2001080849-A1 | METHOD OF TREATING CANCER | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2001-11-01 | — | — | WO | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | DNMT1, DNMT3B, DNMT3A | MCL1 133/4885GAA 2743/4885KDM4E 656/4885 |
| US-20080009544-A1 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors | ACHE, BCHE, CHRNB1 | MCL1 4551/4885GAA 489/4885KDM4E 1482/4885 |
| US-20040047852-A1 | Method of treating cancer | CAT, SOD3, SOD1 | MCL1 697/4885GAA 179/4885KDM4E 4084/4885 |
| US-20070142462-A1 | Method of Treating Cancer | CAT, SOD3, SOD1 | MCL1 697/4885GAA 179/4885KDM4E 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.